$RVMDRevolution Medicines, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
  Iambic Therapeutics is maintaining the momentum generated by its recent mega round and Big Pharma partnerships by gearing up to go public.
  fiercebiotech · 12d ago
• Opinion: STAT+: The NIH budget should be $100 billion per year
  “We should be strengthening our investment in the NIH, not dismantling it,” writes Reed Jobs.
  stat · 13d ago
• A breakthrough pancreatic cancer drug won approval. They still struggle to access it
  When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied.
  stat · 26d ago
• Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
  Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
  biopharma_dive · 1mo ago
• RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
  The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall re…
  biospace · 1mo ago
• Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more
  Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer treatment Rasonque. The drug stunned researchers and spurred excitement in…
  endpoints · 1mo ago
• RevMed could become ‘next oncology titan’ with Rasonque nod
  A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities.
  biospace · 1mo ago
• RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
  The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.
  biospace · 1mo ago
• STAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatment
  The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.
  stat · 1mo ago
• FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
  The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanc…
  fda_press · 1mo ago